Glenmark Pharmaceuticals Q2 FY27 Results Preview: What the Numbers Show So Far

Track the latest Glenmark Pharmaceuticals Ltd. share price on Univest alongside these quarterly numbers.

Investors tracking pharma stocks are watching Glenmark Pharmaceuticals Q2 results as the September 2026 quarter draws to a close. Glenmark Pharmaceuticals has delivered a mixed run of quarterly numbers over the last year, and Glenmark Pharmaceuticals Q2 results will show whether the operating momentum seen in June 2026 can hold. This preview uses only data the company has already reported, without projecting figures for the quarter still underway.

When Are Glenmark Pharmaceuticals Q2 results Expected?

Glenmark Pharmaceuticals has not officially announced a date for Glenmark Pharmaceuticals Q2 results. Based on the company's historical pattern, Glenmark Pharmaceuticals Q2 results are typically declared in the last week of October or the first two weeks of November. Glenmark Pharmaceuticals Ltd. has broadly stuck to that cadence in recent years. Once the board meeting date is confirmed through an exchange filing, it will be public on the NSE and BSE websites.

What to Expect From Glenmark Pharmaceuticals Q2 results

The useful way to frame Glenmark Pharmaceuticals Q2 results is around trends already visible in recent quarters, not forecasts. The June 2026 quarter showed operating margin just above 20 percent and net profit of Rs 483 crore, up from Rs 301 crore in March 2026. Whether this holds into September 2026 is a key question for Glenmark Pharmaceuticals Q2 results. Investors will also watch whether specialty and domestic formulations keep contributing to growth, and whether margin stays in the low-to-mid twenties seen outside the unusually strong September 2025 quarter.

Q1 FY27 Performance Ahead of Glenmark Pharmaceuticals Q2 results

In the quarter ended June 2026, Glenmark Pharmaceuticals reported revenue of Rs 4,018 crore, operating profit of Rs 805 crore and an operating margin of 20.03 percent, with net profit of Rs 483 crore. This was a sequential improvement over March 2026, when net profit was Rs 301 crore on revenue of Rs 3,771 crore. This June 2026 base is what analysts will use once Glenmark Pharmaceuticals Q2 results are announced.

Q2 FY26 Base Quarter for Year-on-Year Context

The year-on-year base for Glenmark Pharmaceuticals Q2 results is September 2025 (Q2 FY26), an unusually strong quarter. Glenmark Pharmaceuticals Ltd. reported revenue of Rs 6,047 crore, operating margin of 39 percent and net profit of Rs 610 crore, well above surrounding quarters. Because this base was so much higher than the quarters before and after it, a plain year-on-year comparison should be read with that context rather than as a clean measure of underlying growth.

Recent Trend Across Quarters

Revenue moved from Rs 3,264 crore in June 2025 to Rs 6,047 crore in September 2025, then Rs 3,901 crore, Rs 3,771 crore and Rs 4,018 crore since. Margin spiked to 39 percent in September 2025 before settling near 20 to 22 percent. Net profit moved from Rs 47 crore to Rs 403 crore, Rs 301 crore and Rs 483 crore over the same period, the backdrop for Glenmark Pharmaceuticals Q2 results.

Key Factors to Watch in Glenmark Pharmaceuticals Q2 results

The US generics business, pricing and new approvals remain swing factors ahead of Glenmark Pharmaceuticals Q2 results. Domestic formulations and the specialty portfolio matter for growth quality. Input costs and plant inspection outcomes are also worth tracking.

Valuation Snapshot Ahead of Glenmark Pharmaceuticals Q2 results

At a current price of around Rs 2,416, Glenmark Pharmaceuticals Ltd. trades at a trailing PE of about 21.85x and a price-to-book ratio of 6.49x, against a book value of Rs 372. Return on equity is 23.6 percent and dividend yield is 0.21 percent. The price sits closer to its 52-week high of Rs 2,537.6 than its low of Rs 1,792.6. This is a current snapshot, not a signal of what Glenmark Pharmaceuticals Q2 results will show.

What to Watch When Glenmark Pharmaceuticals Q2 results Are Announced

Key markers once Glenmark Pharmaceuticals Q2 results are out include sequential growth from the June 2026 base and whether margin holds the recent 20 to 22 percent band.

Open a free Demat account with Univest and track Glenmark Pharmaceuticals' Q2 results as they happen.

Conclusion

Glenmark Pharmaceuticals Q2 results will show whether the margin steadiness seen since December 2025 is durable. Based on data through June 2026, the company looks to be operating in a calmer band after the outsized September 2025 quarter, though actual September 2026 numbers are still awaited. It is worth reading the coming results against this longer trend rather than in isolation.

Start investing with Univest today and get timely updates when Glenmark Pharmaceuticals announces its Q2 numbers.

Create your Univest trading account now to follow Glenmark Pharmaceuticals through results season.

Compare Glenmark Pharmaceuticals against peers using the Univest stock screener before the results are announced.

Also read – CEAT Q2 Results FY27 Preview

Also read – Cello World Q2 Results FY27 Preview

#CC0000;background:#FFF3F3;padding:10px 16px;">Disclaimer: Univest Securities Private Limited is a SEBI-registered Research Analyst (Registration No. INH000013776). The information in this article is compiled from company financial disclosures and public market data and is provided for educational purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Past performance and historical financial trends are not indicative of future results. Investors should consult a SEBI-registered investment adviser before making any investment decision.

When will Glenmark Pharmaceuticals announce its Q2 results?

Glenmark Pharmaceuticals has not officially confirmed a date for its Q2 FY27 results yet. Based on past years, the company typically announces second-quarter results in late October or early November, though the exact date will only be known once the board meeting intimation is filed with the exchanges.

What was Glenmark Pharmaceuticals' net profit in the June 2026 quarter?

In the quarter ended June 2026, Glenmark Pharmaceuticals reported a net profit of Rs 483 crore on revenue of Rs 4,018 crore, with an operating margin of 20.03 percent.

Why was Glenmark Pharmaceuticals' September 2025 quarter unusually strong?

The September 2025 quarter (Q2 FY26) saw revenue of Rs 6,047 crore and an operating margin of 39 percent, both significantly higher than the quarters before and after it, making it an unusually high base for year-on-year comparisons.

What is Glenmark Pharmaceuticals' current valuation?

As of the current market price of around Rs 2,416, Glenmark Pharmaceuticals trades at a trailing PE of about 21.85x, a price-to-book ratio of 6.49x, and a return on equity of 23.6 percent.